GLP-1 meds via telehealth: what the hype leaves out

What did @coffeewithsonia_vsg actually say?

She's about a week post-first-dose on compounded semaglutide, one year out from a vertical sleeve gastrectomy, and still ravenously hungry. Her words: "I literally be starving." She skipped the anti-nausea patch because she thought combining it with the injection was too much. She's genuinely confused about why the medication isn't suppressing her appetite yet, and she's asking her audience whether anyone else experienced ongoing hunger during their first week.

To her credit, she's not making miracle claims. She's not telling anyone to buy anything. She's documenting a confusing first week in real time, which is actually a more honest format than most GLP-1 content on this platform. She also acknowledges she might just be doing something wrong, which shows some self-awareness. The core question she's raising, whether week one hunger is normal on semaglutide, is a legitimate clinical question worth answering properly.

Does the science back this up?

Yes, actually. Hunger suppression in the first week of semaglutide is not reliable, and that's not a bug. It's how the drug is designed to work. The clinical reality is that semaglutide reaches steady-state plasma concentrations after several weeks of dose escalation, not after one injection.

The STEP 1 trial (Wilding et al., 2021, NEJM) used a 16-week escalation protocol before participants hit the 2.4 mg maintenance dose of semaglutide. Appetite suppression, measured by validated hunger scales, improved progressively over that escalation period. Week one data wasn't even the focus because clinicians don't expect significant appetite changes that early. A 2022 paper by Blundell et al. in Diabetes, Obesity and Metabolism specifically examined semaglutide's effect on appetite regulation and found that GLP-1 receptor agonists modulate gastric emptying and hypothalamic hunger signaling in a dose-dependent, time-dependent manner. One shot at a starter dose is unlikely to produce the "food noise" reduction people see in testimonials, which almost always come from people already at therapeutic dose.

What did they get wrong (or right)?

She got the frustration right, but the framing is slightly off. Saying "I don't know what I'm doing wrong" implies the drug should have worked by now. It shouldn't, necessarily. That's not a personal failure; that's pharmacokinetics.

The sleeve gastrectomy piece is also worth addressing. She says "the hunger is back" one year post-op, which is a documented phenomenon. Research by Peterli et al. (2018, JAMA) found that ghrelin suppression after sleeve gastrectomy can diminish over time, and weight regain and hunger return are common at the one to two year mark. So her hunger isn't mysterious. It's expected given her surgical history.

Her decision to skip the anti-nausea patch deserves a flag. She doesn't say what patch she means, but some telehealth GLP-1 protocols include compounded ondansetron or scopolamine patches to reduce early GI side effects. Skipping it because she thought it was "too much" is her call, but she describes stomach weirdness anyway. There's no safety violation in what she did, but it's worth noting she may have experienced more discomfort than necessary.

One thing she should not have implied: that the compounded version "didn't work as well as it should." Compounded semaglutide is not FDA-approved and has not been demonstrated in controlled trials to be bioequivalent to Wegovy or Ozempic. The two should not be assumed equivalent.

What should you actually know?

If you start compounded or brand-name semaglutide and you're still hungry in week one, that is normal. GLP-1 receptor agonists work through mechanisms that take weeks to build, including slowing gastric emptying, reducing ghrelin signaling, and modulating dopamine pathways tied to food reward. You are not failing the drug. The drug is still loading.

Second, if you've had bariatric surgery, your hunger and weight trajectory post-op is not the same as someone who hasn't had surgery. GLP-1 medications can still be effective in post-bariatric patients, and there is emerging data supporting their use in this population, but your baseline is different and your expectations should be calibrated accordingly.

Third, compounded semaglutide is not the same as brand-name semaglutide. The FDA has explicitly stated that compounded drugs are not proven to be safe or effective in the same way approved drugs are. If you are using a compounded version, you should be doing so through a licensed prescriber who is monitoring you, not based on a TikTok protocol.

• Week one hunger on semaglutide is normal and expected.
• Dose escalation protocols exist for a reason: therapeutic effect builds over weeks, not days.
• Post-sleeve hunger returning at one year is well-documented and not a mystery.
• Compounded semaglutide has not been shown to be bioequivalent to brand-name versions.